May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
A Randomized Trial Assessing Microbial Eradication and Clinical Efficacy of 1% Azithromycin Ophthalmic Solution vs. Tobramycin in Adult Subjects With Bacterial Conjunctivitis
Author Affiliations & Notes
  • M.B. Abelson
    Ophthalmic Research Associates, North Andover, MA
    Schepens Eye Research Institute & Harvard Medical School, Boston, MA
  • E.E. Protzko
    Seidenberg & Protzko Eye Associates, Bel Air, MD
    University of Maryland–School of Medicine, Baltimore, MD
  • A.M. Shapiro
    Ophthalmic Research Associates, North Andover, MA
  • AzaSite Clinical Study Group
    Ophthalmic Research Associates, North Andover, MA
  • Footnotes
    Commercial Relationships  M.B. Abelson, InSite Vision, C; E.E. Protzko, None; A.M. Shapiro, Ophthalmic Research Associates, E.
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 3589. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M.B. Abelson, E.E. Protzko, A.M. Shapiro, AzaSite Clinical Study Group; A Randomized Trial Assessing Microbial Eradication and Clinical Efficacy of 1% Azithromycin Ophthalmic Solution vs. Tobramycin in Adult Subjects With Bacterial Conjunctivitis . Invest. Ophthalmol. Vis. Sci. 2006;47(13):3589.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the efficacy of azithromycin ophthalmic solution 1.0% in DuraSite (AzaSite) compared to tobramycin ophthalmic solution USP, 0.3% in pediatric and adult patients with bacterial conjunctivitis.

Methods: : Seven hundred forty–six subjects, aged one year or older, with presumptive bacterial conjunctivitis were dosed two times daily (BID) for 2 days followed by once a day (QD) for 3 days with AzaSite 1% or four times a day for 5 days with tobramycin 0.3% in a, multi–center, double–masked, randomized, active–controlled study. The primary clinical efficacy variable was clinical resolution rate. Clinical resolution was attained when the score of the three ocular signs (palpebral and bulbar conjunctival redness, conjunctival discharge) was zero at the test–of–cure visit (Day 6 and 7). Anti–microbial efficacy was evaluated as bacterial eradication rate at each of 3 clinic visits.

Results: : Three hundred and sixteen subjects had positive bacterial cultures. In this pivotal phase 3 clinical trial powered to demonstrate equivalency, the results show that the clinical resolution rate of AzaSite is equivalent to tobramycin even though Azasite was dosed less frequently. The bacterial eradication rates were similarly equivalent. Prominent organisms eradicated by both tobramycin and AzaSite were Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Staphylococcus epidermidis, and other viridans Streptococcus .

Conclusions: : The results indicate that clinical resolution of bacterial conjunctivitis and eradication of bacterial species prevalent in acute bacterial conjunctivitis can be accomplished with a 5–day dosing of AzaSite 1.0% instilled BID on days 1 and 2 and QD on days 3–5. This regimen of reduced dosing frequency was just as effective as tobramycin dosed QID for 5 days.

Keywords: clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • antibiotics/antifungals/antiparasitics • bacterial disease 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×